Financials data is unavailable for this security.
View more
Year on year SMS Pharmaceuticals Ltd grew revenues 35.86% from 5.22bn to 7.09bn while net income improved from a loss of 70.59m to a gain of 498.26m.
| Gross margin | 30.10% |
|---|---|
| Net profit margin | 7.62% |
| Operating margin | 12.32% |
| Return on assets | 5.55% |
|---|---|
| Return on equity | 11.38% |
| Return on investment | 8.40% |
More ▼
Cash flow in INRView more
In 2024, SMS Pharmaceuticals Ltd increased its cash reserves by 393.16%, or 287.32m. The company earned 501.25m from its operations for a Cash Flow Margin of 7.07%. In addition the company generated 306.79m cash from financing while 520.72m was spent on investing.
| Cash flow per share | 10.84 |
|---|---|
| Price/Cash flow per share | 22.14 |
| Book value per share | 66.57 |
|---|---|
| Tangible book value per share | 66.28 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.55 |
|---|---|
| Quick ratio | 0.7104 |
| Total debt/total equity | 0.5063 |
|---|---|
| Total debt/total capital | 0.3361 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 805.82%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.32% |
|---|---|
| Div growth rate (5 year) | 9.86% |
| Payout ratio (TTM) | 4.28% |
| EPS growth(5 years) | 4.47 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 110.23 |
More ▼
